Quantcast
Last updated on April 23, 2014 at 11:53 EDT

Latest Lintuzumab Stories

2014-02-28 08:25:51

SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML). (Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO) "We are very pleased to receive this orphan drug...

2013-12-18 13:10:26

Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers.  This finding may lead to therapies capable of preventing the progression of these diseases. MDS primarily affects older individuals, with approximately 12,000 new cases diagnosed each year. In MDS, a person’s blood is not able to make one or more types of healthy blood cells — red blood cells, white blood cells or...

2013-12-16 08:25:29

- Initial results for BL-8040 show substantial mobilization of cancer cells and signs of robust cancer cell death (apoptosis) - JERUSALEM, Dec. 16, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040 drug candidate in a Phase 2 clinical trial for patients with relapsed or refractory acute...

2013-12-10 04:22:24

-- Interim Results of Tosedostat in Combination with Chemotherapy or Hypomethylating Agents in First-line Demonstrate 54 Percent Complete Response Rate and 12-Month Median Survival -- SEATTLE, Dec. 10, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced promising interim results from an investigator-initiated Phase 2 clinical trial of tosedostat in combination with cytarabine or decitabine in newly diagnosed older patients with acute myeloid...

2013-12-09 14:01:57

Findings from nationwide study led by Children's Mercy researcher highlighted at American Society of Hematology Meeting The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML). Post-treatment relapse rates are a major indicator of potential for long-term survival in children with the disease....

2013-12-09 08:27:09

Initial Data Demonstrate Safety and Antileukemic Activity in Older Patients with Acute Myeloid Leukemia NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, were presented in a poster session on Saturday, December 7, 2013 at the American Society of Hematology's (ASH) 55th Annual Meeting and...

2013-12-03 16:25:12

Company to Hold Conference Call and Webcast at 9:00 am ET, Wednesday, December 4, 2013 SAN DIEGO, Dec. 3, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced a regulatory update after receiving feedback from the U.S. Food and Drug Administration (FDA) on the development of quizartinib (AC220), the Company's lead...

2013-12-02 08:30:29

Initial Data Show That Fractionated Doses of Actimab-A in Combination with LDAC are Safe and Have Antileukemic Activity in Older Patients with Acute Myeloid Leukemia NEW YORK, Dec. 2, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, reported today that data from an abstract of a study investigating the Company's...

2013-11-18 08:27:51

Actinium Expects Single Trial Required for Regulatory Approval NEW YORK, Nov. 18, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative, targeted payload immunotherapeutics for the treatment of advanced cancers, provided a corporate update on its two most advanced clinical programs. Kaushik J. Dave Ph.D., MBA, President and Chief Executive Officer, hosted a call on November 11, 2013 to discuss...

2013-06-25 04:21:15

SEATTLE, June 25, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today issued the following statement regarding the notification of the U.S. Food and Drug Administration (the "FDA") partial clinical hold on tosedostat (IND 075503), the Company's aminopeptidase inhibitor under development for the treatment of blood-related cancers, that is being studied in an investigator-sponsored trial and not by CTI. CTI's primary development programs are the ongoing...